文献速递胸部肿瘤

劳拉替尼治疗ALK阳性非小细胞肺癌:全球2期研究结果

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
PubMed 文献 · Lancet Oncol · 2018-11-06

这项全球2期研究纳入276例ALK阳性或ROS1阳性晚期非小细胞肺癌患者,劳拉替尼100 mg口服每日一次。在初治ALK阳性患者中客观缓解率为90.0%(95%CI 73.5-97.9),在既往至少一种ALK酪氨酸激酶抑制剂治疗失败患者中为47.0%(95%CI 39.9-54.2)。

要点

  • 初治ALK阳性患者客观缓解率90.0%(95%CI 73.5-97.9),颅内客观缓解率66.7%(95%CI 9.4-99.2)。
  • 既往至少一种ALK酪氨酸激酶抑制剂患者客观缓解率47.0%(95%CI 39.9-54.2),颅内客观缓解率63.0%(95%CI 51.5-73.4)。
  • 最常见治疗相关不良事件为高胆固醇血症(81%)和高甘油三酯血症(60%),各16%为3-4级。

核心结论

  • 劳拉替尼在初治及既往ALK酪氨酸激酶抑制剂治疗失败的ALK阳性非小细胞肺癌患者中均显示显著的全身和颅内抗肿瘤活性。
  • 作者认为劳拉替尼可能成为ALK阳性非小细胞肺癌一线或后续治疗的有效选择。

研究设计与样本

  • 全球2期研究,纳入组织学或细胞学确诊的ALK阳性或ROS1阳性晚期非小细胞肺癌患者,按ALK/ROS1状态及既往治疗分入EXP1-6六个扩展队列。
  • 患者接受劳拉替尼100 mg口服每日一次持续给药,21天为一周期。
  • 主要终点为独立中心审查评估的总体和颅内肿瘤缓解,在ALK阳性患者汇总亚组中评估。
  • 2015年9月15日至2016年10月3日共纳入276例患者:EXP1队列30例初治ALK阳性;EXP2队列27例和EXP3A队列32例既往克唑替尼治疗(EXP3A含既往化疗);EXP3B队列28例既往一种非克唑替尼ALK酪氨酸激酶抑制剂(含或不含化疗);EXP4队列66例和EXP5队列46例既往两种或三种ALK酪氨酸激酶抑制剂(含或不含化疗);EXP6队列47例ROS1阳性任何既往治疗。
  • EXP4队列1例患者在接受劳拉替尼前死亡,被排除在安全性分析集之外。

主要发现

  • 初治ALK阳性患者(EXP1)30例中27例达到客观缓解,客观缓解率90.0%(95%CI 73.5-97.9)。
  • EXP1队列中3例基线有可测量中枢神经系统病灶,其中2例达到颅内客观缓解,颅内客观缓解率66.7%(95%CI 9.4-99.2)。
  • 既往至少一种ALK酪氨酸激酶抑制剂患者(EXP2-5)198例中93例达到客观缓解,客观缓解率47.0%(95%CI 39.9-54.2);基线有可测量中枢神经系统病灶的81例中51例达到颅内客观缓解,颅内客观缓解率63.0%(95%CI 51.5-73.4)。
  • 仅既往克唑替尼治疗患者(EXP2-3A)59例中41例达到客观缓解,客观缓解率69.5%(95%CI 56.1-80.8);既往一种非克唑替尼ALK酪氨酸激酶抑制剂患者(EXP3B)28例中9例达到客观缓解,客观缓解率32.1%(95%CI 15.9-52.4);既往两种或以上ALK酪氨酸激酶抑制剂患者(EXP4-5)111例中43例达到客观缓解,客观缓解率38.7%(95%CI 29.6-48.5)。
  • 基线有可测量中枢神经系统病灶患者中,EXP2-3A队列23例中20例达到颅内客观缓解,颅内客观缓解率87.0%(95%CI 66.4-97.2);EXP3B队列9例中5例达到颅内客观缓解,颅内客观缓解率55.6%(95%CI 21.2-86.3);EXP4-5队列49例中26例达到颅内客观缓解,颅内客观缓解率53.1%(95%CI 38.3-67.5)。

关键数值与推荐

  • 所有患者中最常见治疗相关不良事件为高胆固醇血症(275例中224例,81%;其中43例,16%为3-4级)和高甘油三酯血症(275例中166例,60%;其中43例,16%为3-4级)。
  • 严重治疗相关不良事件发生于275例中19例(7%),7例(3%)因治疗相关不良事件永久终止治疗。
  • 未报告治疗相关死亡。

临床怎么用

  • 作者认为劳拉替尼可能成为ALK阳性非小细胞肺癌一线或后续治疗的有效选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lorlatinib is a potent, brain-penetrant, third-generation inhibitor of ALK and ROS1 tyrosine kinases with broad coverage of ALK mutations. In a phase 1 study, activity was seen in patients with ALK-positive non-small-cell lung cancer, most of whom had CNS metastases and progression after ALK-directed therapy. We aimed to analyse the overall and intracranial antitumour activity of lorlatinib in patients with ALK-positive, advanced non-small-cell lung cancer. METHODS: In this phase 2 study, patients with histologically or cytologically ALK-positive or ROS1-positive, advanced, non-small-cell lung cancer, with or without CNS metastases, with an Eastern Cooperative Oncology Group performance status of 0, 1, or 2, and adequate end-organ function were eligible. Patients were enrolled into six different expansion cohorts (EXP1-6) on the basis of ALK and ROS1 status and previous therapy, and were given lorlatinib 100 mg orally once daily continuously in 21-day cycles. The primary endpoint was overall and intracranial tumour response by independent central review, assessed in pooled subgroups of ALK-positive patients. Analyses of activity and safety were based on the safety analysis set (ie, all patients who received at least one dose of lorlatinib) as assessed by independent central review. Patients with measurable CNS metastases at baseline by independent central review were included in the intracranial activity analyses. In this report, we present lorlatinib activity data for the ALK-positive patients (EXP1-5 only), and safety data for all treated patients (EXP1-6). This study is ongoing and is registered with ClinicalTrials.gov, number NCT01970865. FINDINGS: Between Sept 15, 2015, and Oct 3, 2016, 276 patients were enrolled: 30 who were ALK positive and treatment naive (EXP1); 59 who were ALK positive and received previous crizotinib without (n=27; EXP2) or with (n=32; EXP3A) previous chemotherapy; 28 who were ALK positive and received one previous non-crizotinib ALK tyrosine kinase inhibitor, with or without chemotherapy (EXP3B); 112 who were ALK positive with two (n=66; EXP4) or three (n=46; EXP5) previous ALK tyrosine kinase inhibitors with or without chemotherapy; and 47 who were ROS1 positive with any previous treatment (EXP6). One patient in EXP4 died before receiving lorlatinib and was excluded from the safety analysis set. In treatment-naive patients (EXP1), an objective response was achieved in 27 (90·0%; 95% CI 73·5-97·9) of 30 patients. Three patients in EXP1 had measurable baseline CNS lesions per independent central review, and objective intracranial responses were observed in two (66·7%; 95% CI 9·4-99·2). In ALK-positive patients with at least one previous ALK tyrosine kinase inhibitor (EXP2-5), objective responses were achieved in 93 (47·0%; 39·9-54·2) of 198 patients and objective intracranial response in those with measurable baseline CNS lesions in 51 (63·0%; 51·5-73·4) of 81 patients. Objective response was achieved in 41 (69·5%; 95% CI 56·1-80·8) of 59 patients who had only received previous crizotinib (EXP2-3A), nine (32·1%; 15·9-52·4) of 28 patients with one previous non-crizotinib ALK tyrosine kinase inhibitor (EXP3B), and 43 (38·7%; 29·6-48·5) of 111 patients with two or more previous ALK tyrosine kinase inhibitors (EXP4-5). Objective intracranial response was achieved in 20 (87·0%; 95% CI 66·4-97·2) of 23 patients with measurable baseline CNS lesions in EXP2-3A, five (55·6%; 21·2-86·3) of nine patients in EXP3B, and 26 (53·1%; 38·3-67·5) of 49 patients in EXP4-5. The most common treatment-related adverse events across all patients were hypercholesterolaemia (224 [81%] of 275 patients overall and 43 [16%] grade 3-4) and hypertriglyceridaemia (166 [60%] overall and 43 [16%] grade 3-4). Serious treatment-related adverse events occurred in 19 (7%) of 275 patients and seven patients (3%) permanently discontinued treatment because of treatment-related adverse events. No treatment-related deaths were reported. INTERPRETATION: Consistent with its broad ALK mutational coverage and CNS penetration, lorlatinib showed substantial overall and intracranial activity both in treatment-naive patients with ALK-positive non-small-cell lung cancer, and in those who had progressed on crizotinib, second-generation ALK tyrosine kinase inhibitors, or after up to three previous ALK tyrosine kinase inhibitors. Thus, lorlatinib could represent an effective treatment option for patients with ALK-positive non-small-cell lung cancer in first-line or subsequent therapy. FUNDING: Pfizer.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018. PMID: 30413378. doi:10.1016/S1470-2045(18)30649-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。